Ubs Group Ag Fibrogen Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Fibrogen Inc stock. As of the latest transaction made, Ubs Group Ag holds 24,663 shares of FGEN stock, worth $8,632. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,663

Previous 69,359 64.44%

Holding current value

$8,632

Previous $61,000 85.25%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.33 - $1.26 $14,749 - $56,316	-44,696 Reduced 64.44%	24,663 $9,000
Q2 2024 Aug 13, 2024	SELL	$0.89 - $2.36 $28,222 - $74,837	-31,711 Reduced 31.38%	69,359 $61,000
Q1 2024 May 13, 2024	BUY	$0.73 - $2.73 $14,593 - $54,575	19,991 Added 24.66%	101,070 $237,000
Q4 2023 Feb 09, 2024	BUY	$0.38 - $0.91 $30,546 - $73,150	80,385 Added 11582.85%	81,079 $72,000
Q3 2023 Nov 09, 2023	SELL	$0.79 - $2.83 $80,376 - $287,929	-101,742 Reduced 99.32%	694 $0
Q2 2023 Aug 11, 2023	BUY	$2.49 - $20.59 $193,893 - $1.6 Million	77,869 Added 316.97%	102,436 $276,000
Q1 2023 May 12, 2023	SELL	$15.95 - $25.18 $2.73 Million - $4.3 Million	-170,888 Reduced 87.43%	24,567 $458,000
Q4 2022 Feb 08, 2023	BUY	$13.27 - $17.73 $2.04 Million - $2.73 Million	153,891 Added 370.25%	195,455 $3.13 Million
Q3 2022 Nov 10, 2022	SELL	$11.4 - $14.6 $497,712 - $637,421	-43,659 Reduced 51.23%	41,564 $541,000
Q2 2022 Aug 10, 2022	SELL	$7.94 - $12.96 $1.45 Million - $2.37 Million	-182,849 Reduced 68.21%	85,223 $900,000
Q1 2022 May 16, 2022	BUY	$12.02 - $16.79 $293,348 - $409,759	24,405 Added 10.02%	268,072 $3.22 Million
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $617,794 - $957,488	-62,215 Reduced 20.34%	243,667 $3.44 Million
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $2.75 Million - $7.19 Million	269,830 Added 748.45%	305,882 $3.13 Million
Q2 2021 Aug 13, 2021	SELL	$18.57 - $35.68 $1.02 Million - $1.96 Million	-54,862 Reduced 60.34%	36,052 $960,000
Q1 2021 May 12, 2021	BUY	$31.0 - $55.72 $2.74 Million - $4.92 Million	88,320 Added 3404.78%	90,914 $3.16 Million
Q4 2020 Feb 11, 2021	BUY	$37.09 - $48.97 $11,201 - $14,788	302 Added 13.18%	2,594 $96,000
Q3 2020 Nov 12, 2020	SELL	$40.47 - $45.5 $4.06 Million - $4.56 Million	-100,198 Reduced 97.76%	2,292 $94,000
Q2 2020 Jul 31, 2020	SELL	$32.57 - $42.83 $2.68 Million - $3.53 Million	-82,411 Reduced 44.57%	102,490 $4.15 Million
Q1 2020 May 01, 2020	BUY	$23.3 - $45.96 $530,401 - $1.05 Million	22,764 Added 14.04%	184,901 $6.43 Million
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $1.08 Million - $1.51 Million	31,364 Added 23.98%	162,137 $6.95 Million
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $2.48 Million - $3.24 Million	66,937 Added 104.86%	130,773 $4.84 Million
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $543,355 - $858,882	-15,467 Reduced 19.5%	63,836 $2.89 Million
Q1 2019 May 14, 2019	SELL	$42.83 - $59.91 $2.96 Million - $4.14 Million	-69,070 Reduced 46.55%	79,303 $4.31 Million
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $4.33 Million - $6.86 Million	113,955 Added 331.09%	148,373 $6.87 Million
Q3 2018 Nov 14, 2018	BUY	$56.3 - $67.25 $60,128 - $71,823	1,068 Added 3.2%	34,418 $2.09 Million
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $6.18 Million - $8.94 Million	-137,593 Reduced 80.49%	33,350 $2.09 Million
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $7.63 Million - $10.4 Million	168,162 Added 6046.82%	170,943 $7.9 Million
Q4 2017 Feb 14, 2018	SELL	$41.95 - $60.1 $1.51 Million - $2.16 Million	-35,904 Reduced 92.81%	2,781 $132,000
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $1.26 Million - $2.03 Million	37,675 Added 3730.2%	38,685 $2.08 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-125 Reduced 11.01%	1,010 $33,000
Q1 2017 Nov 14, 2017	BUY	N/A	1,135	1,135 $28,000

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account